Experts praise CLL trial for including elderly with coexisting conditions Oncology Nurse Advisor Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had ... |
